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Background: Hepatitis B virus (HBV) transcription and replication are essentially restricted to hepatocytes. Based on
the HBV enhancer and promoter complex that links hepatic glucose metabolism to its transcription and replication,
HBV adopts a regulatory system that is unique to the hepatic gluconeogenic genes. CRTC2, the CREB-regulated
transcription coactivator 2, is a critical switch modulating the gluconeogenic program in response to both hormonal
and intracellular signals. However, the relationship between CRTC2 and HBV transcription and replication remains
unclear.
Methods: To analyze the influence of CRTC2 on HBV transcription and replication, CRTC2 expression construct or
siRNA was cotransfected with plasmids containing enhancer II/core promoter complex-controlled luciferase or 1.3×
wtHBV genome in Huh-7 cells. Luciferase activity, HBV core protein expression, HBV transcripts, and DNA replication
intermediates were measured by luciferase assays, western blots, real-time polymerase chain reaction (PCR), and
Southern blots, respectively. Forskolin (FSK) or phosphorylation-defective CRTC2 mutants were further utilized to
elucidate the potential mechanism. siRNA against peroxisome proliferator-activated receptor-γ coactivator 1α
(PGC1α) was also used to examine the mediator involved in CRTC2-regulated HBV biosynthesis in Huh-7 cells.
Results: CRTC2 overexpression increased HBV transcription and replication in Huh-7 cells, including levels of core
protein expression, mRNA, and DNA replication intermediates. Correspondingly, CRTC2 knock down by siRNA
reduced HBV biosynthesis. FSK treatment strongly enhanced the effect of CRTC2 through triggering the
dephosphorylation and nuclear entry of CRTC2. The phosphorylation-defective mutant (S171A/S275A) of CRTC2
localized in the nucleus and was constitutively active, which dramatically promoted HBV transcription and
replication similar to FSK-treated wild-type CRTC2. Knock down of PGC1α, whose expression was induced by CRTC2,
greatly compromised the enhancing effect of CRTC2 on HBV transcription and replication.
Conclusions: Our results clearly indicate that non-phosphorylated CRTC2 strongly enhances HBV biosynthesis
through inducing PGC1α expression. Further study of the mechanisms will elucidate the importance of metabolic
signals on HBV transcription and replication, and offer insight into potential targets for developing anti-HBV agents.
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Hepatitis B virus (HBV) is the prototypical member
of hepadnaviruses, a small enveloped DNA virus
family preferentially targeting the liver [1-3]. Multiple
studies have implicated that HBV transcription and
replication might be regulated by transcription fac-
tors capable of mediating hepatic gluconeogenesis* Correspondence: zhaofei@wh.iov.cn; hukgh@wh.iov.cn
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stated.[2,4]. The cAMP-responsive element-binding protein
(CREB)-regulated transcription coactivator 2 (CRTC2)
is a critical switch promoting the gluconeogenic pro-
gram in the liver [5]. Under normal physiological
conditions, CRTC2 is phosphorylated at Ser171 and
Ser275 by SIK1 (salt-inducible kinase 1) and MARK2
(microtubule affinity-regulating kinase 2), respectively.
Phosphorylation of CRTC2 triggers phosphorylation-
dependent binding to 14-3-3 proteins, which seques-
ters CRTC2 in the cytoplasm [6,7]. In response to
fasting, CRTC2 is dephosphorylated and translocates. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ther stimulates the expression of downstream gluco-
neogenic genes [5]. The dephosphorylation of CRTC2
at Ser171 and Ser275 is triggered by the calcium-
regulated Ser/Thr phosphatase calcineurin following
exposure to cAMP and calcium [5,8-10]. Thus, the
dephosphorylated and nuclear-translocated CRTC2 is
considered to be the active form [8]. Forskolin (FSK)
treatment dramatically raises cellular cAMP and cal-
cium levels and dephosphorylates CRTC2, which ren-
ders it active by allowing it to translocate to the
nucleus [10]. The calcineurin inhibitor cyclosporine A
(CsA) disrupts the cAMP-induced dephosphorylation
and nuclear translocation of CRTC2, but it has no ef-
fect on a phosphorylation-defective CRTC2 mutant
(S171A/S275A) [8]. Because it cannot be phosphory-
lated at these two sites, the S171A/S275A mutant
remains active in the nucleus [11,12].
The HBV genome comprises a partially double-stranded
DNA that binds a variety of liver-enriched nuclear recep-
tors, some of which are also critical regulators implicated in
gluconeogenesis [4,6,7,13,14]. As a coactivator of key
gluconeogenesis genes, peroxisome proliferator-activated
receptor-γ coactivator 1α (PGC1α) expression is also
stimulated by active CRTC2. It has been proved that
PGC1α coactivates HBV transcription and replication
through hepatocyte nuclear factor-4α (HNF4α) and fork-
head transcription factor FOXO1, which has also been con-
firmed in our previously published data [15,16]. Thus, we
sought to study the link between HBV transcription activity
and hepatic metabolic state [16-20], especially the unknown
relationship of CRTC2 with HBV biosynthesis.
To address these issues, HBV transcription and rep-
lication activities were analyzed by measuring enhan-
cer II/core promoter complex-controlled luciferase
activity, core protein expression, mRNA levels, and
DNA replication intermediates in Huh-7 cells trans-
fected with HBV constructs together with the indi-
cated constructs. FSK and phosphorylation-defective
CRTC2 mutants were also employed to elucidate the
potential mechanism of CRTC2’s effects on HBV
transcription and replication. Our results showed that
CRTC2 increased HBV biosynthesis, and this effect
was dramatically promoted by Ser171 and Ser275 de-
phosphorylation, which stimulated CRTC2 nuclear
translocation and transformed CRTC2 into the active
form. Importantly, the enhancement of CRTC2 on
HBV transcription and replication was mediated by
inducing PGC1α expression. Considering the critical
roles of CRTC2 and PGC1α in the gluconeogenic
program, our findings indicate the importance of un-
derstanding the regulatory effects of metabolic signals
on HBV transcription and replication, which could
offer insight into novel targets for anti-HBV therapy.Results
CRTC2 enhances HBV transcription
Due to its enhancer and promoter composition, HBV
transcription and replication can be regulated by nutri-
tional signals that control hepatic glucose metabolism
[2]. As a critical switch promoting the hepatic gluconeo-
genic program, CRTC2 attracted our interest for its role
in HBV transcription and replication. The enhancer II/
core promoter sequence regulates the transcription of
3.5-kb pregenomic RNA (pgRNA) that initiates the key
step for HBV replication [6,21], so we first examined the
effect of CRTC2 overexpression on the enhancer II/core
promoter. For this aim, CRTC2 plasmid (p-CRTC2) was
transfected into Huh-7 cells together with pGL-3-ENII-
luc, a plasmid that expressed luciferase under the con-
trol of HBV enhancer II/core promoter complex. CRTC2
expression in transfected Huh-7 cells was confirmed by
western blot analysis detecting the FLAG-tag (Additional
file 1: Figure S1A). The results presented in Figure 1A
clearly showed elevated luciferase activity in the pres-
ence of overexpressed CRTC2 in Huh-7 cells, indicating
that transfected CRTC2 activated the enhancer II/core
promoter complex. In 1.3× wtHBV plasmid-transfected
Huh-7 cells, exogenous CRTC2 expression also in-
creased HBV transcripts (Figure 1B). Two different siR-
NAs against CRTC2 and control siRNA were applied to
investigate the effect of endogenous CRTC2 on HBV
transcription. Both siRNAs against CRTC2 clearly re-
duced CRTC2 protein levels, but not the control siRNA
(Additional file 1: Figure S1B). CRTC2 knock down by
siRNA significantly reduced enhancer II/core promoter-
controlled luciferase expression (Figure 1C) and HBV
transcripts (Figure 1D), indicating the regulatory role of
CRTC2 in HBV transcription. Because knock down of
endogenous CRTC2 only led to a mild reduction in
HBV transcription, FSK and exogenous CRTC2 were
further applied to explore the potential mechanism in-
volved in CRTC2 enhanced HBV transcription and
replication.
FSK robustly enhances CRTC2-induced HBV transcription
and replication
As a cAMP inducer, FSK strongly promotes CRTC2 de-
phosphorylation and nuclear translocation [5], which
stimulates downstream gene expression [17,22]. CRTC2
was primarily localized in the cytoplasm in the absence
of FSK, and upon FSK treatment, it was dephosphory-
lated (Additional file 2: Figure S2B) and translocated
into the nucleus (Additional file 2: Figure S2A). Consid-
ering the active form of nuclear-translocated CRTC2 [5],
we examined whether FSK treatment influenced its
regulatory role in HBV transcription and replication.
Huh-7 cells were treated with 10 μM FSK 16 hours



























Figure 1 CRTC2 enhances HBV transcription. (A) Luciferase activity in Huh-7 cells transfected with pGL-3-ENII-luc and p-CRTC2. (B) HBV mRNA
levels in Huh-7 cells transfected with 1.3× wtHBV plasmid and p-CRTC2. (C-D) The effect of CRTC2 knock down on luciferase activity (C) and HBV
mRNA levels (D) in pGL-3-ENII-luc and 1.3× wtHBV plasmid-transfected Huh-7 cells, respectively. *p < 0.05.
Tian et al. Virology Journal 2014, 11:30 Page 3 of 8
http://www.virologyj.com/content/11/1/30In accordance with our previously described results,
CRTC2 had marginal effects on luciferase activity. Not-
ably, this effect was robustly promoted by FSK treatment
(Figure 2A). Similar FSK-induced enhancements were
observed for core protein expression (Figure 2B), HBV















Figure 2 FSK robustly enhances CRTC2-induced HBV transcription an
pGL-3-ENII-luc and p-CRTC2 in the presence or absence of FSK. (B-D) HBV c
tion intermediates (D) in Huh-7 cells transfected with p-CRTC2 and 1.3× wintermediates (Figure 2D) in Huh-7 cell transfected with
1.3× wtHBV construct. Even in the absence of exogen-
ous CRTC2, FSK treatment increased HBV biosynthesis
to some extent (Figure 2A-D), possibly due to the exist-
ence of endogenous CRTC2. However, the basal level of















d replication. (A) Luciferase activity in Huh-7 cells transfected with
ore protein expression (B), HBV mRNA levels (C), and HBV DNA replica-
tHBV plasmid, in the presence or absence of FSK. *p < 0.05; **p < 0.01.
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with CRTC2 siRNA (Additional file 3: Figure S3). Over-
all, these results indicate that FSK dramatically enhanced
CRTC2-induced HBV transcription and replication.
Phosphorylation-defective CRTC2 mutants strongly
upregulate HBV biosynthesis
Under basal conditions, CRTC2 is sequestered in the cyto-
plasm through phosphorylation at Ser171 and Ser275
[5,23]. Nuclear translocation and subsequent downstream
gene transcription requires dephosphorylating at these two
sites [8,24]. Mutations at individual (Ser171Ala, Ser275Ala)
or both sites (Ser171Ala/Ser275Ala) were carried out to
generate phosphorylation-defective mutants (Additional
file 2: Figure S2B), which could not be phosphorylated and
primarily localized in the nucleus (Additional file 2:
Figure S2A). To investigate whether FSK enhanced
CRTC2-induced HBV biosynthesis through dephosphory-
lating Ser171 and Ser275, phosphorylation-defective mu-
tant constructs were transfected into Huh-7 cells, together
with pGL-3-ENII-luc (Figure 3A) or 1.3× wtHBV construct
(Figure 3B-D). Compared to wild-type CRTC2, single-site
mutation (S171A or S275A) significantly increased lucifer-
ase activity (Figure 3A), core protein expression (Figure 3B),
HBV transcript levels (Figure 3C), and the number of
DNA replication intermediates (Figure 3D). Notably,
phosphorylation-defective mutations at both sites (S171A/
S275A) induced HBV biosynthesis to the greatest degree
(Figure 3A-D). FSK treatment significantly promoted the
increasing effect of wild-type CRTC2 and both single-site
mutants of CRTC2 (S171A or S275A), but it only slightly
enhanced activity of the double-site mutated CRTC2
(S171A/S275A) (Figure 3A-D), which was possibly due to-actin
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Figure 3 Phosphorylation-defective CRTC2 mutants strongly upregula
mutation of CRTC2 (S171A, S275A, and S171A/S275A) on luciferase activity
HBV core protein expression (B), HBV mRNA level (C), and HBV DNA replica
plasmid and wild-type or mutated CRTC2 in the presence or absence of FSactivity of the endogenous wild-type CRTC2. These results
indicate that FSK enhanced CRTC2-induced HBV biosyn-
thesis by dephosphorylating Ser171/Ser275 and triggering
CRTC2 nuclear entry.
CRTC2 enhances HBV biosynthesis through inducing
PGC1α expression
PGC1α is one of the downstream genes stimulated by
CRTC2 [25,26]. Our data clearly showed that CRTC2 in-
duced PGC1α mRNA expression, which was further sig-
nificantly promoted by FSK (Figure 4A). In accordance
with previously published data [15,17], exogenous
PGC1α expression significantly upregulated HBV tran-
scription (Figure 4B). Therefore, we investigated
whether CRTC2-enhanced HBV biosynthesis was medi-
ated by PGC1α expression. To address this issue, siRNA
was applied to knock-down PGC1α expression in Huh-
7 cells transfected with p-CRTC2 and pGL-3-ENII-luc
(Figure 4C) or 1.3× wtHBV (Figure 4D-F). The knock
down efficiency of PGC1α was confirmed by quantitative
PCR (Additional file 4: Figure S4A and B). As previously
shown, CRTC2 strongly upregulated HBV biosynthesis
following FSK treatment. However, PGC1α knock down
significantly attenuated the enhancing effect of CRTC2/
FSK on luciferase activity (Figure 4C), HBV transcript
levels (Figure 4D), core protein expression (Figure 4E),
and DNA replication intermediates (Figure 4F). These re-
sults suggest that CRTC2 enhancing HBV biosynthesis
was dependent on the induction of PGC1α expression.
Discussion
The CRTC family consists of three isoforms (CRTC1,
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te HBV biosynthesis. (A) The effect of a phosphorylation-defective
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tion intermediates (D) in Huh-7 cells transfected with 1.3× wtHBV
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Figure 4 CRTC2 enhances HBV replication by inducing PGC1α expression. (A) PGC1α expression level in Huh-7 cells transfected with
p-CRTC2 with or without FSK treatment. (B) HBV transcript amounts in Huh-7 cells transfected with 1.3× wtHBV plasmid and p-PGC1α. (C) Effect
of PGC1α knock down on luciferase activity in Huh-7 cells transfected with pGL-3-ENII-luc and p-CRTC2 with FSK treatment. (D-F) Effect of PGC1α
knock down on HBV mRNA level (D), HBV core protein expression (E), and HBV DNA replication intermediates (F) in Huh-7 cells transfected with
1.3× wtHBV plasmid and p-CRTC2 with FSK treatment. *p < 0.05; **p < 0.01.
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CRTC1 and CRTC3 play important roles in energy balance
[22], whereas CRTC2 induces the gluconeogenic program
and thus promotes glucose homeostasis during fasting in
liver [5]. It has been shown that HBV biosynthesis can be
regulated by signals involved in the gluconeogenic program.
Thus, we were interested in investigating whether the hor-
monal and energy-sensing coactivator CRTC2 influenced
HBV transcription and replication.
In response to FSK, CRTC2 is dephosphorylated and
transported to the nucleus, which is a critical step in
stimulating downstream gene expression, including that
of PGC1α [5,27]. CRTC2 promotes PGC1α expression
through its role as a coactivator of CREB [8]. The
CREB-CRTC pathway triggered by hormonal and nutri-
ent signals has been extensively characterized, and the
CREB-CRTC/PGC1α signal transduction pathway has
been shown to mediate glucose homeostasis in the liver
[8,28,29]. In addition, the effect of the insulin signaling
pathway on HBV pgRNA synthesis and viral replication
has been proven to be PGC1α dependent [20]. Collect-
ively, these observations have led to the suggestion thatthe regulation of HBV transcription and replication may
utilize similar signal transduction pathways as those in-
volved in the expression of key hepatic metabolic genes
[17,30-32].
Our results clearly demonstrated that HBV transcription
and replication was regulated by CRTC2. Overexpression
of exogenous CRTC2 increased HBV biosynthesis in Huh-7
cells, whereas its knock down had the opposite effect. Hep-
atic CRTC2 is regulated through phosphorylation at Ser171
and Ser275 by SIKs and members of the AMP-activated
protein kinase (AMPK), such as MARK2 [22]. As a result,
phosphorylated CRTC2 was sequestered in the cytoplasm
through phosphorylation-dependent interactions with 14-
3-3 proteins [5,22]. FSK treatment significantly enhanced
CRTC2-induced HBV transcription and replication, which
was mediated by dephosphorylating CRTC2 and triggering
its nuclear translocation. Interestingly, phosphorylation-
defective mutants with single-site mutations (S171A or
S275A) showed only mild enhancement compared to wild-
type CRTC2, which was possibly due to the remaining
phosphorylation site. FSK application further promoted the
increasing effect of S171A or S275A. In accordance with
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S275A with both two defective phosphorylation sites dra-
matically increased HBV transcription and replication, but
FSK did not have a significant effect on S171A/S275A-in-
duced activity. The slight increase of S171A/S275A-induced
HBV biosynthesis following FSK treatment might be ex-
plained by the presence of endogenous wild-type CRTC2,
which could still be affected by FSK. Most current anti-
HBV drugs are nucleotide/nucleoside analogs, which are
double-edged swords given the emergence of drug-resistant
HBV mutants and potential disease flare-ups [19]. Indeed,
nucleotide/nucleoside analogs fail to eliminate the HBV
cccDNA pool and usually require prolonged or life-long
treatment [19]. Therefore, the ideal therapy should combine
both virus-specific and host-directed treatments. Our re-
sults clearly showed that the glucose homeostasis regulator
CRTC2 has the potential to modulate HBV transcription
and replication in Huh-7 cells, suggesting that viral biosyn-
thesis may be regulated by hepatic metabolic state. The ob-
servation that diabetic patients are more likely to suffer
acute HBV infections than non-diabetic patients supports
the contention that metabolic signaling through CRTC2
can influence the outcome of viral infection [33,34]. To
mimic the physiological starving condition, glucose-free
media was applied in our preliminary experiments, but
transfected cells failed to survive under these conditions.
For this reason, FSK, which was previously shown to simu-
late a starvation state, was applied to cells as an alternative
approach [18]. Under feeding conditions, CRTC2 is seques-
tered in the cytoplasm, and fasting or FSK treatment de-
phosphorylated CRTC2 and transported it to the nucleus
[22], where it enhanced HBV transcription and replication.
Our work builds on the elaborate and exciting report pub-
lished by Shaul’s group, which clearly demonstrated that
PGC1α regulates HBV transcription and replication in re-
sponse to nutritional cues [17]. Collectively, our data and
published reports concerning HBV and nutrition conditions
suggest that HBV patients should completely avoid food
deprivation conditions. It has also been reported that mal-
nutrition might be a key element responsible for HBV in-
fection [2]. Thus, proper nutrition, including the digestion
of complex carbohydrates to avoid hypoglycemia that re-
sults in increased glucagon levels, may be a critical compo-
nent of novel anti-HBV therapeutic strategies. Concerning
the dependency of HBV transcription and replication on
momentary nutritional status, the optimal time to collect
blood samples from patients for HBV copy number testing
should be also taken into consideration.
Elucidating the regulatory role of the CRTC2/
PGC1α signaling pathway and the underlying mech-
anism will reveal important molecular processes
involved in HBV biosynthesis and elucidate the rela-
tionship between metabolic signals and HBV replica-
tion during natural infection. Such knowledge couldcontribute to the development of novel therapeutic
approaches.
Conclusions
In summary, our results demonstrate a novel up-regulatory
role of CRTC2 on HBV biosynthesis. CRTC2 activated the
enhancer II/Core promoter complex, increased core pro-
tein expression, and elevated HBV transcripts and DNA
replication intermediates. This enhancing effect was dra-
matically promoted by CRTC2 dephosphorylation. Import-
antly, CRTC2 enhanced HBV transcription and replication
by inducing PGC1α expression.
Materials and methods
Plasmid constructs
The 1.3× wtHBV plasmid (1.3× wtHBV) encoding 1.3
copies of the HBV genome (adw strain) was kindly
provided by Dr. Yosef Shaul [6]. The pGL-3-ENII-luc con-
struct expressing luciferase under the control of HBV
ENII/core promoter complex (nt.1403–1803) was a gift
from Dr. Jing-hsiung James Ou [35]. The p-CRTC2 plasmid
was constructed by inserting wild-type human CRTC2
cDNA into pCDNA3.1 FLAG+ and the phosphorylation-
defective CRTC2 mutants (S171A, S275A, and S171A/
S275A) were generated by site-directed mutagenesis based
on the p-CRTC2 plasmid. pSuper vector [36] containing
the human H1 promoter was used as the backbone to gen-
erate siRNA expression plasmids against CRTC2 and
PGC1α. The applied siRNA sequences were CRTC2
siRNA1 5′- gcc caa tgt taa cca gat t -3′, siRNA2 5′- cag cga
gat cct cga aga atg-3′ and PGC1α siRNA 5′- ggt gga ttg
aag tgg tgt a -3′ [17].
Cell culture and transfection
The human hepatoma cell line Huh-7 were cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% (vol/vol) fetal bovine serum, 100 U/ml penicillin
and 100 μg/ml streptomycin (all from Gibco Life Tech-
nologies, USA) at 37ºC under a 5% CO2 atmosphere.
Transfection was performed in 10 cm cell culture dishes
containing 1 × 106 Huh-7 cells by using Lipofectamine
2000 according to the manufacturer’s instructions (Invi-
trogen, USA). The following constructs were applied for
transfection: 1.3× wtHBV (3 μg), pGL-3-ENII-luc (3 μg),
p-CRTC2 (9 μg), p-CRTC2 (S171A) (9 μg), p-CRTC2
(S275A) (9 μg), p-CRTC2 (S171A/S275A) (9 μg), CRTC2
siRNA (9 μg), and PGC1α siRNA (9 μg). The same
amount of vector lacking the corresponding insert was
used as controls. When indicated, cells were treated with
10 μM FSK (Sigma, USA) 16 hours post-transfection.
Quantitative real-time PCR
HBV transcript and PGC1α expression analyses were per-
formed as described previously [17]. Briefly, transfected
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total RNA isolation, and cDNA were synthesized using Pre-
meScript RT reagent kit (Takara, Japan) following the man-
ufacturer’s instructions. Quantitative real-time PCR was
performed using SYBR Green Realtime PCR Master Mix
(Toyobo, Japan) in the Mx3000P qPCR System (Agilent
Technologies, USA). The results were normalized to the
housekeeping gene β-actin in all assays. The following
primers were used: HBV, 5′- ctc agc tct gta tcg aga agc c
-3′ (sense) and 5′- cag tga gag ggc cca caa att g -3′ (anti-
sense); PGC1α, 5′- tcc tca cag aga cac tag aca g -3′ (sense)
and 5′- ctg gtg cca gta aga gct tct -3′ (antisense); β-actin,
5′- acc gcg aga aga tga ccc ag -3′ (sense) and 5′- cca tct cgt
tct cga agt cca -3′ (antisense).Southern blot analysis
Encapsidated HBV DNA was isolated using the method
described by Guo [37]. Briefly, 1 × 106 transfected cells
were collected 3 days post-transfection and lysed in
300 μl lysis buffer (50 mM Tris–HCl [pH 7.4], 1 mM
EDTA, and 1% NP-40). After centrifugation, the super-
natant was treated with DNase I (100 μg/ml) and RNase
A (100 μg/ml) for 30 minutes at 37°C to remove the
extra-capsid nuclear acid. HBV DNA in the intracellular
core particles was isolated with phenol-chloroform (1:1)
extraction and ethanol precipitation after being released
by digesting capsid proteins with proteinase K in the
presence of 1% sodium dodecyl sulfate (SDS) for 2
hours. Following electrophoresis in a 1.0% agarose gel,
encapsidated HBV DNA was blotted onto a nylon mem-
brane and hybridized with a 32P-labeled HBV-specific
probe. Signals were visualized using Cyclone Plus Stor-
age Phosphor System (Perkin Elmer, USA).Western blot analysis
For protein analysis, 1 × 106 transfected cells were lysed in
300 μl lysis buffer (50 mM Tris–HCl [pH 8.0], 150 mM
NaCl, 0.1% SDS, 1% NP40, 0.5% deoxycholic acid, 0.5% so-
dium azide, and 100 μl/ml phenylmethanesulfonyl fluoride).
The lysates of each sample were electrophoresed with 12%
SDS-PAGE gel and blotted onto PVDF membranes (Immo-
bilon P, Millipore, USA). The blotted membranes were then
incubated with the indicated primary antibodies followed
by the corresponding secondary horseradish peroxidase
(HRP)-conjugated antibodies. Signals were visualized
using a DAB Western Blot kit (Thermo Fisher Scientific,
USA). The following antibodies were used, monoclonal
rabbit anti-CRTC2 (Epitomics, USA), rabbit anti-phospho-
CRTC2 (Ser171) (Bioss, Scotland), polyclonal rabbit
anti-HBc (DAKO, Denmark), monoclonal mouse anti-
FLAG (Invitrogen, USA), monoclonal mouse anti-β-actin
(Interchim, France), and goat anti-mouse IgG and goat
anti-rabbit IgG (Proteintech, USA).Luciferase assay
Huh-7 cells were transfected with pGL-3-ENII-luc to-
gether with the indicated constructs. Luciferase activity
was measured 48 hours post-transfection using the Lu-
ciferase Assay System (Promega, USA) according to the
manufacturer’s instructions. Results are shown as the ac-
tivity fold increase of firefly luciferase against Renilla lu-
ciferase, which was used for transfection efficiency
adjustments.
Statistical analysis
All bar graphs are shown as the mean ± standard error (SE)
from at least three independent experiments, and results
shown for Southern or western blotting are representative
images selected from more than three independent experi-
ments. Statistical differences were assessed with unpaired
two-tailed Student’s t-tests. Differences were considered to
be statistically significant when p < 0.05.
Additional files
Additional file 1: Figure S1. (A) CRTC2 expression in Huh-7 cells 48
hours post p-CRTC2 or mock transfection. CRTC2 expression was analyzed
by detecting FLAG-tag. (B) Knock down efficiency of CRTC2 siRNA on
endogenous CRTC2 protein level.
Additional file 2: Figure S2. (A) Effect of FSK or phosphorylation-
defective mutations (S171A/S275A) on CRTC2 localization in Huh-7 cells
24 hours post-transfection. CRTC2 was detected by FLAG-tag. (B) The
phosphorylation level of CRTC2 in Huh-7 cells transfected with wildtype
or phosphorylation-defective mutant of CRTC2 (S171A) in the presence or
absence of FSK.
Additional file 3: Figure S3. CRTC2 siRNA attenuated the FSK
enhancing effect on luciferase activity controlled by Enhancer II/Core
promoter in Huh-7 cells. *p < 0.05.
Additional file 4: Figure S4. (A) Knock down efficiency of siRNA on
endogenous PGC1α expression in Huh-7 cells. (B) Knock down efficiency
of siRNA on CRTC2/FSK induced PGC1α expression in Huh-7 cells.
*p < 0.01.
Abbreviations
HBV: Hepatitis B virus; CRTC2: Camp response element-binding protein
(CREB)-regulated transcription coactivator 2; PGC1α: Peroxisome proliferator-
activated receptor-γ coactivator 1α; CREB: Camp response element-binding
protein; FSK: Forskolin.
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